The treatment landscape for inflammatory bowel disease (IBD) has entered an exciting new era of precision medicine, as innovative therapies such as interleukin-23 (IL-23) inhibitors offer renewed hope for sustained remission and improved quality of life. Rapidly emerging clinical trial …
The treatment landscape for inflammatory bowel disease (IBD) has entered an exciting new era of precision medicine, as innovative therapies such as interleukin-23 (IL-23) inhibitors offer renewed hope for sustained remission and improved quality of life. Rapidly emerging clinical trial …
Major depressive disorder (MDD) is often recurrent, and achieving remission does not eliminate the risk of future episodes. Each recurrent episode can deepen the neurobiological, psychiatric, medical, economic, and quality-of-life burden while increasing the risk of future episodes. Yet, relapse …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians …
Effective pain management is more complex than ever. As opioid prescribing guidance continues to evolve, clinicians must stay current with the latest evidence to deliver safe and patient-centered care. The FDA Opioid Analgesic REMS Education Blueprint and the 2022 CDC …
What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …